Skip to main content
AmigoFish

Gene Therapy for Inherited Retinal Diseases with Opus Genetics' Dr. George Magrath

From Cell & Gene: The Podcast · · 20 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1810482/fan_mail/new)

In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness. Built on the foundational science of Dr. Jean Bennett and leveraging the legacy of Luxturna, Magrath shares how Opus is developing subretinal AAV-based therapies targeting seven distinct mutations. He also explains why gene therapy is particularly well-suited to IRDs, shares compelling early clinical data, and discusses the promise of early intervention in preserving vision and enabling proper neural development.

Subscribe to the podcast! Apple (https://podcasts.apple.com/us/podcast/cell-gene-the-podcast/id1574496063) | Spotify (https://open.spotify.com/show/78NSjRuHndVhI5VHWWAMya) | YouTube (https://music.youtube.com/playlist?list=PLFXsCNKV78rWyuxay7hXQFo0rVyAXAdwX)

Visit my website: Cell & Gene (https://www.cellandgene.com/)

Connect with me on LinkedIn (https://www.linkedin.com/in/erinharris/)

Back to Cell & Gene: The Podcast · Report a problem